Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Merger or Acquisition (September 2014)

13 slides from Auxilium Pharmaceuticals's merger presentation, Sep 16, 2014

  1. Slide 1: Endo-Auxilium: Creating Value, A Compelling Business Combination Proposal

    Filedfollowing Subject The Endo September ©2014 by Auxilium: Presents Endo Company: Endo 16,Pharmaceuticals International presentation a2014 Value Compelling Auxilium Creating isplc Business Pharmaceuticals, to Inc. (Commission Proposal beAll used rights Combination during reserved. File Inc. Endo’s

  2. Slide 2: Additional Information

    Additional ADDITIONAL This combination or prospectus, SECURITY CAREFULLY statement CERTAIN Endo regarding SEC sources included All the 2© 2014 more SEC related trademarks, communication on and Endo indicated March registration by incertain the (if logos INFORMATION Information any proxy Endo HOLDERS

  3. Slide 3: Forward-Looking Statements

    Forward-Looking This but “look forward-looking place SEC Form looking limited with to plans; combined and governmental operations facilities, business All hereof. 3© law. 2014 Auxilium are forward-looking the communication Endo; and undue 8-K forward,” •not Endo to: combined unpredictable if stateme

  4. Slide 4: Proposed Transaction Overview

    Proposed Transaction 25% Premium: Consideration: Financing: 4© 2014 to Endo Auxilium’s Transaction Price: Endo Value: Pharmaceuticals Approximately $28.10 intends $2.2 closing Overview per billion to price fund share Inc. equal transaction on inAll September cash mix rights and of cash through reser

  5. Slide 5: Endo's Substantial Opportunity

    Endo’s Substantial Opportunity The Enhance Expand Generate Create 5© 2014 combination opportunity company Endo Proposal proposal R&D the significant premium to long Pharmaceuticals capabilities participate provides with isof term Value toEndo synergy and enhanced maximize organic Creating immediate

  6. Slide 6: Substantial Offer for Auxilium Shareholders

    Substantial Offer Endo 44% 25% 28% 35% Premium Endo’s 6© 2014 42% 24% offer Price Endo proposal toprice Value Premium 9/12/14 Pharmaceuticals represents offor $28.10 Close Auxilium Premium per substantial Inc. share, Shareholders Alltomix rights premium 30 of Daycash reserved. VWAP for andAuxilium s

  7. Slide 7: Demonstrated Record of Value Enhancing Transactions

    Demonstrated Paladin Establish Boca Expand Grupo Add Sumavel® Leverage 7© 2014 significant platform Pharmacal Farmaceutico Endo Labs global generics Irish commercial DosePro® Pharmaceuticals for for Record domicile footprint near-term in cash R&D organic August Somar and capabilities in of platform

  8. Slide 8: Meeting Endo's Strategic Direction

    Endo Meeting Maximizing Continued Lean Pursuing Value Addition Opportunity Combined Enhanced Combination 8© 2014 and executing creating Endo or of accretive efficient operating investment companies exceeding Auxilium’s the for Pharmaceuticals Aligns will combination strategic Xiaflex® growth enhance

  9. Slide 9: Compelling Strategic Rationale

    Compelling Auxilium’s Endo Drive Support Optimize Combined Highly 9© 2014expects increased Endo complementary development Auxilium’s company 12 Strategic Pharmaceuticals toFDA-approved adoption optimize will broader Rationale ofportfolio Xiaflex® be and Auxilium’s well portfolio continued Inc. produ

  10. Slide 10: Select Highlights of Complementary Product Portfolio

    Select Highlights Men’s ©2014 10 Health Endo Pharmaceuticals / Urology of Complementary Orthopedics Inc. All/Product rights Pain Other reserved. Portfolio Specialty

  11. Slide 11: Strong Pro Forma Financial Profile

    Strong Enhanced Significant Robust Immediate Deal Synergies ©2014 11 structure Pro Endo financial driven would near accretion Forma synergy Pharmaceuticals enables and returns be byFinancial long opportunity in complementary and continued addition that term enhanced Profile are revenue Inc. to leads

  12. Slide 12: Endo's Substantial Opportunity; Prepared to Engage

    Endocombination Endo’s Substantial Opportunity The Enhance Expand Generate Create Proposal ©2014 12 Prepared opportunity company Endo proposal R&D the subject significant premium to long Pharmaceuticals capabilities to participate provides with to of term Engage to the Endo synergy and enhanced maxi

  13. Slide 13: Endo-Auxilium: Creating Value

    Endo—Auxilium: Endo September ©2014Presents Endo16,Pharmaceuticals a2014 Value Compelling CreatingInc. Business Proposal All rights Combination reserved.

Auxilium Pharmaceuticals — Merger or Acquisition (September 2014) on 6ix